Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days

NCT02651987 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT02651987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02651987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days
Lead sponsor
Ipsen
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2015
Completion date
October 24, 2019
Enrollment
99 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

midgut neuroendocrine tumours, pancreatic tumours